Evidence map›Paper›PMID 42174504›Full record

ArticleBMC pulmonary medicine2026

Modulator therapy: rates and stages of respiratory bacteriome restoration in cystic fibrosis patients chronically infected with Pseudomonadota.

Olga L Voronina, Natalia N Ryzhova, Marina S Kunda, Ekaterina I Ermolova, Elena L Amelina, Rezuan U Kagazezhev, Alexander L Gintsburg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Olga L VoroninaN.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Gamaleya Str., 18, Moscow, 123098, Russia. olv550@gmail.com.
Natalia N RyzhovaN.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Gamaleya Str., 18, Moscow, 123098, Russia.
Marina S KundaN.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Gamaleya Str., 18, Moscow, 123098, Russia.
Ekaterina I ErmolovaN.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Gamaleya Str., 18, Moscow, 123098, Russia.
Elena L AmelinaPulmonology Research Institute, FMBA of Russia, Orekhovy Boulevard, 28, building 10, Moscow, 115682, Russia.
Rezuan U KagazezhevPulmonology Research Institute, FMBA of Russia, Orekhovy Boulevard, 28, building 10, Moscow, 115682, Russia.
Alexander L GintsburgN.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russia, Gamaleya Str., 18, Moscow, 123098, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic lung infection caused by Pseudomonadota (PCH) in patients with cystic fibrosis (pwCF) is difficult to eradicate. CFTR modulators have a potential role in the prevention of airway infections, but their ability to eradicate chronic infection remains to be investigated. The aim of our study was to evaluate the impact of combination (antibacterial (AT) and modulator (MT)) therapy on the lung bacteriome composition (LBC) in the pwCF cohort.

resultsThe bacteriomes of sputum samples longitudinally collected from 57 Russian adult pwCFs chronically infected with Pseudomonadota CF pathogens (PCH) were analyzed. MT tended to reduce the bacterial load. The LMC did not significantly change in PCH pwCFs that received MT for less than three years. Two-component MT resulted in a temporary decrease in the proportion of the CF pathogen only when combined with a course of AT. Three-component MT has been successful in inducing favorable bacteriome changes (in terms of the abundance and diversity of anaerobic taxa) over a period of more than 3 years but not for all cases of Burkholderiales infection.

conclusionsThe respiratory system damaged by bronchiectasis is susceptible to new infections, so patient management requires constant monitoring of the LBC and replenishment of the therapeutic landscape with both new modulators and new antibacterial drugs.

Indexed as

Anti-Bacterial AgentsChloride Channel AgonistsCystic FibrosisLungPseudomonas InfectionsAdultBacterial LoadCystic Fibrosis Transmembrane Conductance RegulatorDrug Therapy, CombinationFemaleHumansLongitudinal StudiesMalePersistent InfectionRespiratory Tract InfectionsSputumAnti-Bacterial AgentsChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorAnaerobesBacterial loadCF pathogensCFTR modulator therapyCystic fibrosisLung bacteriomeMarker taxaMicrobial diversity

Identifiers

PMID42174504
PMCPMC13371271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.